Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515258 | 0.86 | RAB9A (0.47) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20515253 | 0.79 | PTK2 (0.41) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20515255 | 0.75 | GAA (0.73) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20515292 | 0.75 | HPGD (0.52) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20515251 | 0.74 | HPGD (0.50) | MAPTGAAALDH1A1MAPK1TSHR | |
| SCHEMBL20515268 | 0.73 | GAA (0.53) | MAPTGAAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20515252 | 0.72 | POLB (0.43) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20515283 | 0.72 | MAPT (0.43) | MAPTALDH1A1HPGD | |
| SCHEMBL20515262 | 0.71 | KMT2A (0.50) | GAAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4651272 | 0.70 | MAPT (1.00) | MAPTALDH1A1MAPK1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | MAPT 3974/4885GAA 4811/4885ALDH1A1 2642/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | MAPT 3974/4885GAA 4811/4885ALDH1A1 2642/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | MAPT 3903/4885GAA 4828/4885ALDH1A1 2968/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | MAPT 3954/4885GAA 4811/4885ALDH1A1 2845/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | MAPT 3969/4885GAA 4811/4885ALDH1A1 2828/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | MAPT 3992/4885GAA 4813/4885ALDH1A1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.